| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Staff Development | 9 | 2020 | 62 | 2.270 |
Why?
|
| Career Mobility | 7 | 2020 | 89 | 2.240 |
Why?
|
| Professional Competence | 8 | 2018 | 134 | 2.040 |
Why?
|
| Biomedical Research | 10 | 2018 | 797 | 1.910 |
Why?
|
| Research Personnel | 9 | 2022 | 168 | 1.880 |
Why?
|
| Physicians, Women | 6 | 2020 | 100 | 1.880 |
Why?
|
| Postmenopause | 8 | 2021 | 378 | 1.830 |
Why?
|
| Academic Medical Centers | 6 | 2020 | 688 | 1.780 |
Why?
|
| Faculty, Medical | 6 | 2020 | 309 | 1.650 |
Why?
|
| Career Choice | 6 | 2020 | 210 | 1.630 |
Why?
|
| Neoplasms | 29 | 2023 | 15897 | 1.320 |
Why?
|
| Mentors | 8 | 2022 | 210 | 1.260 |
Why?
|
| Medical Oncology | 11 | 2023 | 1463 | 1.140 |
Why?
|
| Communication | 5 | 2022 | 856 | 1.140 |
Why?
|
| Students | 3 | 2022 | 330 | 1.050 |
Why?
|
| Weight Gain | 4 | 2021 | 470 | 1.010 |
Why?
|
| Mexican Americans | 5 | 2021 | 333 | 0.980 |
Why?
|
| Self Concept | 3 | 2022 | 199 | 0.920 |
Why?
|
| Insulin-Like Growth Factor I | 4 | 2014 | 632 | 0.910 |
Why?
|
| Competency-Based Education | 2 | 2015 | 81 | 0.900 |
Why?
|
| Colorectal Neoplasms | 4 | 2023 | 3700 | 0.860 |
Why?
|
| Body Mass Index | 13 | 2022 | 2238 | 0.750 |
Why?
|
| United States | 30 | 2023 | 15852 | 0.740 |
Why?
|
| Estrogens | 4 | 2014 | 809 | 0.740 |
Why?
|
| Fellowships and Scholarships | 4 | 2014 | 410 | 0.710 |
Why?
|
| Health Equity | 4 | 2022 | 58 | 0.700 |
Why?
|
| Social Identification | 1 | 2020 | 23 | 0.700 |
Why?
|
| Community-Based Participatory Research | 1 | 2020 | 62 | 0.690 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2014 | 98 | 0.690 |
Why?
|
| Breast Neoplasms | 17 | 2022 | 16184 | 0.680 |
Why?
|
| Aspirin | 1 | 2022 | 374 | 0.680 |
Why?
|
| Premenopause | 7 | 2009 | 139 | 0.680 |
Why?
|
| Schools, Medical | 3 | 2017 | 132 | 0.660 |
Why?
|
| Training Support | 5 | 2014 | 26 | 0.630 |
Why?
|
| Curriculum | 3 | 2022 | 913 | 0.610 |
Why?
|
| Interdisciplinary Communication | 3 | 2018 | 276 | 0.590 |
Why?
|
| Program Evaluation | 6 | 2022 | 609 | 0.580 |
Why?
|
| Life Style | 6 | 2019 | 619 | 0.580 |
Why?
|
| Self Efficacy | 2 | 2020 | 300 | 0.570 |
Why?
|
| Diet | 7 | 2015 | 1481 | 0.570 |
Why?
|
| Personnel Turnover | 1 | 2016 | 13 | 0.540 |
Why?
|
| Decision Making, Organizational | 1 | 2016 | 8 | 0.540 |
Why?
|
| Humans | 93 | 2023 | 270370 | 0.520 |
Why?
|
| Leadership | 6 | 2020 | 264 | 0.520 |
Why?
|
| National Cancer Institute (U.S.) | 7 | 2023 | 218 | 0.510 |
Why?
|
| Obesity | 10 | 2022 | 2907 | 0.500 |
Why?
|
| Internationality | 2 | 2015 | 206 | 0.490 |
Why?
|
| Social Skills | 1 | 2015 | 18 | 0.490 |
Why?
|
| Clinical Clerkship | 1 | 2015 | 107 | 0.470 |
Why?
|
| Cross-Sectional Studies | 10 | 2022 | 4476 | 0.460 |
Why?
|
| Female | 60 | 2022 | 148592 | 0.440 |
Why?
|
| Health Services Needs and Demand | 2 | 2013 | 246 | 0.440 |
Why?
|
| Leptin | 4 | 2014 | 305 | 0.440 |
Why?
|
| Carotenoids | 2 | 2005 | 103 | 0.420 |
Why?
|
| Physicians | 1 | 2020 | 866 | 0.400 |
Why?
|
| Health Education | 1 | 2014 | 303 | 0.400 |
Why?
|
| Burnout, Professional | 1 | 2016 | 225 | 0.400 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 1900 | 0.380 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2023 | 196 | 0.370 |
Why?
|
| SEER Program | 5 | 2016 | 1049 | 0.370 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 1415 | 0.360 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 229 | 0.350 |
Why?
|
| Sexual and Gender Minorities | 2 | 2022 | 77 | 0.350 |
Why?
|
| Students, Medical | 1 | 2015 | 421 | 0.350 |
Why?
|
| Health Status Disparities | 2 | 2023 | 318 | 0.340 |
Why?
|
| Receptors, Estrogen | 5 | 2009 | 2159 | 0.330 |
Why?
|
| Middle Aged | 36 | 2023 | 90068 | 0.330 |
Why?
|
| Health Behavior | 6 | 2019 | 601 | 0.320 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 2394 | 0.300 |
Why?
|
| Sex Factors | 6 | 2020 | 2178 | 0.300 |
Why?
|
| Risk Factors | 17 | 2015 | 17832 | 0.290 |
Why?
|
| Research Support as Topic | 1 | 2008 | 120 | 0.290 |
Why?
|
| Smoking | 6 | 2019 | 2545 | 0.280 |
Why?
|
| Adenocarcinoma | 2 | 2023 | 7883 | 0.280 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 875 | 0.270 |
Why?
|
| Aged | 25 | 2023 | 73152 | 0.270 |
Why?
|
| Adult | 29 | 2021 | 81727 | 0.270 |
Why?
|
| Publications | 1 | 2006 | 54 | 0.260 |
Why?
|
| Surveys and Questionnaires | 12 | 2023 | 5921 | 0.260 |
Why?
|
| Body Composition | 2 | 2015 | 605 | 0.260 |
Why?
|
| Phytoestrogens | 2 | 2005 | 25 | 0.260 |
Why?
|
| Nutrition Surveys | 3 | 2019 | 316 | 0.260 |
Why?
|
| Qualitative Research | 3 | 2020 | 652 | 0.250 |
Why?
|
| Organizational Culture | 2 | 2017 | 121 | 0.250 |
Why?
|
| Nutritional Status | 2 | 2005 | 353 | 0.250 |
Why?
|
| Early Detection of Cancer | 3 | 2022 | 1340 | 0.250 |
Why?
|
| Healthcare Disparities | 2 | 2022 | 654 | 0.250 |
Why?
|
| Dietary Fats | 4 | 2011 | 341 | 0.240 |
Why?
|
| Overweight | 1 | 2008 | 484 | 0.240 |
Why?
|
| Risk Assessment | 3 | 2019 | 6775 | 0.230 |
Why?
|
| Survivors | 4 | 2013 | 1022 | 0.230 |
Why?
|
| Male | 30 | 2022 | 128053 | 0.220 |
Why?
|
| Regression Analysis | 6 | 2015 | 1570 | 0.220 |
Why?
|
| Minority Groups | 2 | 2022 | 328 | 0.220 |
Why?
|
| Cardiovascular Diseases | 2 | 2019 | 2221 | 0.210 |
Why?
|
| Achievement | 1 | 2022 | 40 | 0.210 |
Why?
|
| Somatomedins | 1 | 2002 | 74 | 0.200 |
Why?
|
| Texas | 9 | 2020 | 6432 | 0.200 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2014 | 156 | 0.190 |
Why?
|
| Fallopian Tubes | 1 | 2002 | 128 | 0.190 |
Why?
|
| Societies, Medical | 2 | 2006 | 1320 | 0.190 |
Why?
|
| Antioxidants | 1 | 2005 | 522 | 0.190 |
Why?
|
| C-Reactive Protein | 2 | 2015 | 558 | 0.190 |
Why?
|
| Ovariectomy | 1 | 2002 | 371 | 0.190 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2022 | 107 | 0.180 |
Why?
|
| Exercise | 3 | 2021 | 1208 | 0.180 |
Why?
|
| Capacity Building | 1 | 2020 | 29 | 0.180 |
Why?
|
| Community Networks | 1 | 2020 | 45 | 0.180 |
Why?
|
| Data Interpretation, Statistical | 1 | 2002 | 485 | 0.180 |
Why?
|
| Oncologists | 1 | 2022 | 136 | 0.170 |
Why?
|
| Mentoring | 1 | 2022 | 101 | 0.170 |
Why?
|
| Insurance Coverage | 1 | 2022 | 274 | 0.170 |
Why?
|
| Mouth | 1 | 2020 | 124 | 0.170 |
Why?
|
| Sports | 2 | 2011 | 72 | 0.170 |
Why?
|
| Fatty Acids | 1 | 2002 | 442 | 0.170 |
Why?
|
| Dysbiosis | 1 | 2020 | 153 | 0.170 |
Why?
|
| Medicaid | 1 | 2022 | 305 | 0.170 |
Why?
|
| Cholesterol | 1 | 2002 | 659 | 0.160 |
Why?
|
| Learning | 1 | 2022 | 433 | 0.160 |
Why?
|
| Alcohol Drinking | 3 | 2021 | 600 | 0.160 |
Why?
|
| Insulin | 2 | 2015 | 1486 | 0.160 |
Why?
|
| Education, Medical, Graduate | 1 | 2005 | 700 | 0.160 |
Why?
|
| Menstrual Cycle | 2 | 2001 | 62 | 0.160 |
Why?
|
| Demography | 1 | 2020 | 432 | 0.160 |
Why?
|
| Prostatic Neoplasms | 4 | 2005 | 5857 | 0.160 |
Why?
|
| Interviews as Topic | 3 | 2017 | 530 | 0.160 |
Why?
|
| Models, Educational | 2 | 2011 | 94 | 0.150 |
Why?
|
| Risk-Taking | 1 | 2019 | 131 | 0.150 |
Why?
|
| Preventive Medicine | 1 | 2018 | 32 | 0.150 |
Why?
|
| Insulin Resistance | 2 | 2015 | 728 | 0.150 |
Why?
|
| Sleep | 1 | 2021 | 443 | 0.150 |
Why?
|
| Internet | 2 | 2020 | 703 | 0.140 |
Why?
|
| Research | 1 | 2020 | 429 | 0.140 |
Why?
|
| Financing, Organized | 1 | 2017 | 21 | 0.140 |
Why?
|
| Diet Surveys | 1 | 2017 | 119 | 0.140 |
Why?
|
| Breast Carcinoma In Situ | 1 | 2016 | 17 | 0.140 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 725 | 0.140 |
Why?
|
| Focus Groups | 2 | 2017 | 287 | 0.140 |
Why?
|
| Education | 1 | 2017 | 125 | 0.140 |
Why?
|
| Cohort Studies | 5 | 2021 | 9463 | 0.130 |
Why?
|
| Biomarkers, Tumor | 2 | 2016 | 10694 | 0.130 |
Why?
|
| Acculturation | 1 | 2017 | 110 | 0.130 |
Why?
|
| Bacteria | 1 | 2020 | 653 | 0.130 |
Why?
|
| Professional Autonomy | 1 | 2016 | 32 | 0.130 |
Why?
|
| Organizational Objectives | 1 | 2016 | 68 | 0.130 |
Why?
|
| Cause of Death | 1 | 2019 | 779 | 0.130 |
Why?
|
| Women's Health | 2 | 2014 | 202 | 0.130 |
Why?
|
| Dietary Fiber | 2 | 2015 | 129 | 0.130 |
Why?
|
| North Carolina | 1 | 2015 | 82 | 0.130 |
Why?
|
| Carcinoma | 2 | 2004 | 2607 | 0.120 |
Why?
|
| Logistic Models | 5 | 2013 | 3439 | 0.120 |
Why?
|
| Incidence | 7 | 2020 | 5812 | 0.120 |
Why?
|
| Nutrition Policy | 1 | 2015 | 109 | 0.120 |
Why?
|
| Data Collection | 2 | 2014 | 624 | 0.120 |
Why?
|
| Microbiota | 1 | 2020 | 547 | 0.120 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 2058 | 0.120 |
Why?
|
| Social Networking | 1 | 2014 | 27 | 0.120 |
Why?
|
| Health Personnel | 1 | 2020 | 656 | 0.120 |
Why?
|
| C-Peptide | 1 | 2014 | 122 | 0.120 |
Why?
|
| Aromatase Inhibitors | 1 | 2016 | 311 | 0.120 |
Why?
|
| Proportional Hazards Models | 5 | 2019 | 5092 | 0.120 |
Why?
|
| Odds Ratio | 4 | 2005 | 2299 | 0.110 |
Why?
|
| Teaching | 2 | 2017 | 251 | 0.110 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 362 | 0.110 |
Why?
|
| Young Adult | 5 | 2020 | 22138 | 0.110 |
Why?
|
| Diet Records | 3 | 2017 | 81 | 0.110 |
Why?
|
| Concept Formation | 1 | 2012 | 27 | 0.110 |
Why?
|
| Genistein | 2 | 2005 | 74 | 0.110 |
Why?
|
| Tamoxifen | 1 | 2016 | 875 | 0.100 |
Why?
|
| Interprofessional Relations | 1 | 2014 | 209 | 0.100 |
Why?
|
| Public Health | 2 | 2018 | 295 | 0.100 |
Why?
|
| Case-Control Studies | 8 | 2010 | 6201 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2021 | 13371 | 0.100 |
Why?
|
| Educational Status | 2 | 2022 | 389 | 0.100 |
Why?
|
| Behavioral Medicine | 1 | 2011 | 15 | 0.100 |
Why?
|
| Isoflavones | 2 | 2005 | 74 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2016 | 513 | 0.100 |
Why?
|
| Cholesterol, LDL | 1 | 2015 | 575 | 0.100 |
Why?
|
| Language Arts | 1 | 2011 | 4 | 0.100 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2016 | 841 | 0.100 |
Why?
|
| Feeding Behavior | 2 | 2015 | 819 | 0.100 |
Why?
|
| Perception | 1 | 2013 | 350 | 0.100 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 13998 | 0.090 |
Why?
|
| Language | 1 | 2013 | 327 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2015 | 676 | 0.090 |
Why?
|
| Mastectomy | 1 | 1997 | 1553 | 0.090 |
Why?
|
| Patient Preference | 1 | 2013 | 229 | 0.090 |
Why?
|
| Age Factors | 3 | 2019 | 5462 | 0.090 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 263 | 0.090 |
Why?
|
| Diabetes Mellitus | 3 | 2017 | 1046 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2015 | 1270 | 0.090 |
Why?
|
| Congresses as Topic | 1 | 2012 | 299 | 0.090 |
Why?
|
| Homeostasis | 1 | 2015 | 926 | 0.090 |
Why?
|
| Interleukin-6 | 1 | 2014 | 1051 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 2 | 2005 | 368 | 0.090 |
Why?
|
| Models, Theoretical | 1 | 2014 | 806 | 0.090 |
Why?
|
| Writing | 1 | 2011 | 104 | 0.090 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2009 | 33 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2016 | 1229 | 0.080 |
Why?
|
| Motor Activity | 1 | 2013 | 714 | 0.080 |
Why?
|
| Nitrosamines | 1 | 2009 | 50 | 0.080 |
Why?
|
| Testicular Neoplasms | 2 | 2007 | 560 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2017 | 5773 | 0.080 |
Why?
|
| Physical Fitness | 1 | 2009 | 125 | 0.080 |
Why?
|
| Cognition | 1 | 2015 | 969 | 0.080 |
Why?
|
| Hormone Replacement Therapy | 1 | 2011 | 214 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 743 | 0.080 |
Why?
|
| Censuses | 1 | 2008 | 15 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2002 | 1516 | 0.080 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2008 | 61 | 0.080 |
Why?
|
| Professional Practice | 2 | 2006 | 80 | 0.070 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 921 | 0.070 |
Why?
|
| Survival Analysis | 4 | 2019 | 9292 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 1 | 2008 | 453 | 0.070 |
Why?
|
| Inflammation | 3 | 2003 | 2510 | 0.070 |
Why?
|
| Germinoma | 1 | 2007 | 82 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2002 | 4785 | 0.070 |
Why?
|
| Infant, Low Birth Weight | 1 | 2007 | 170 | 0.070 |
Why?
|
| Peer Review, Research | 1 | 2006 | 66 | 0.060 |
Why?
|
| Residence Characteristics | 1 | 2008 | 357 | 0.060 |
Why?
|
| Cryptoxanthins | 1 | 2005 | 3 | 0.060 |
Why?
|
| Xanthophylls | 1 | 2005 | 5 | 0.060 |
Why?
|
| Zeaxanthins | 1 | 2005 | 10 | 0.060 |
Why?
|
| Sitosterols | 1 | 2005 | 10 | 0.060 |
Why?
|
| Biomarkers | 2 | 2014 | 5048 | 0.060 |
Why?
|
| Kaempferols | 1 | 2005 | 9 | 0.060 |
Why?
|
| Lutein | 1 | 2005 | 16 | 0.060 |
Why?
|
| Boron | 1 | 2005 | 12 | 0.060 |
Why?
|
| Isomerism | 1 | 2005 | 66 | 0.060 |
Why?
|
| Vomiting | 1 | 2007 | 361 | 0.060 |
Why?
|
| beta Carotene | 1 | 2005 | 73 | 0.060 |
Why?
|
| Telephone | 2 | 2016 | 160 | 0.060 |
Why?
|
| Research Design | 1 | 2011 | 1573 | 0.060 |
Why?
|
| Job Satisfaction | 1 | 2005 | 124 | 0.060 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2007 | 261 | 0.060 |
Why?
|
| Menopause | 1 | 2004 | 161 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2001 | 4323 | 0.060 |
Why?
|
| Comorbidity | 3 | 2016 | 2391 | 0.060 |
Why?
|
| Workload | 1 | 2005 | 200 | 0.060 |
Why?
|
| Hypertension | 1 | 2013 | 1596 | 0.050 |
Why?
|
| Lung Neoplasms | 4 | 2014 | 12020 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 590 | 0.050 |
Why?
|
| Carcinoma, Ductal | 1 | 2004 | 144 | 0.050 |
Why?
|
| Hypolipidemic Agents | 1 | 2005 | 187 | 0.050 |
Why?
|
| Program Development | 2 | 2016 | 262 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2004 | 236 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2004 | 424 | 0.050 |
Why?
|
| California | 2 | 2014 | 212 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2010 | 2100 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2009 | 1032 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2007 | 558 | 0.050 |
Why?
|
| Pyridines | 1 | 2009 | 1311 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2010 | 4648 | 0.050 |
Why?
|
| Endometrial Neoplasms | 1 | 2011 | 1388 | 0.050 |
Why?
|
| Mexico | 1 | 2022 | 275 | 0.050 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2002 | 154 | 0.050 |
Why?
|
| Radioimmunoassay | 1 | 2001 | 203 | 0.050 |
Why?
|
| Luteinizing Hormone | 1 | 2001 | 165 | 0.050 |
Why?
|
| Quality of Life | 2 | 2013 | 4771 | 0.050 |
Why?
|
| DNA Damage | 1 | 2009 | 1982 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2020 | 39744 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2022 | 2853 | 0.050 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2001 | 224 | 0.050 |
Why?
|
| Urban Population | 1 | 2002 | 279 | 0.040 |
Why?
|
| Genes, BRCA2 | 1 | 2002 | 321 | 0.040 |
Why?
|
| Prevalence | 1 | 2008 | 3355 | 0.040 |
Why?
|
| Genes, BRCA1 | 1 | 2002 | 396 | 0.040 |
Why?
|
| Body Height | 1 | 2001 | 234 | 0.040 |
Why?
|
| G1 Phase | 1 | 2000 | 305 | 0.040 |
Why?
|
| Rural Population | 1 | 2002 | 291 | 0.040 |
Why?
|
| Adolescent | 7 | 2015 | 32661 | 0.040 |
Why?
|
| Software Design | 1 | 1999 | 48 | 0.040 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 1999 | 31 | 0.040 |
Why?
|
| Cyclins | 1 | 2000 | 467 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 15191 | 0.040 |
Why?
|
| Fenretinide | 1 | 1999 | 100 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 983 | 0.040 |
Why?
|
| Progesterone | 1 | 2001 | 711 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2000 | 530 | 0.040 |
Why?
|
| Estradiol | 1 | 2001 | 828 | 0.040 |
Why?
|
| Nutrition Assessment | 1 | 1999 | 175 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 214 | 0.040 |
Why?
|
| Fruit | 2 | 2015 | 302 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2009 | 2161 | 0.030 |
Why?
|
| Sexism | 1 | 2017 | 55 | 0.030 |
Why?
|
| Vegetables | 2 | 2015 | 330 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 5565 | 0.030 |
Why?
|
| Energy Intake | 2 | 2015 | 522 | 0.030 |
Why?
|
| Aged, 80 and over | 5 | 2016 | 30934 | 0.030 |
Why?
|
| Health Services Research | 1 | 2018 | 243 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2017 | 163 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2018 | 310 | 0.030 |
Why?
|
| Age of Onset | 1 | 1998 | 852 | 0.030 |
Why?
|
| Food Handling | 1 | 2015 | 23 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2022 | 937 | 0.030 |
Why?
|
| Sodium, Dietary | 1 | 2015 | 36 | 0.030 |
Why?
|
| Cigarette Smoking | 1 | 2017 | 102 | 0.030 |
Why?
|
| Alcoholism | 1 | 2019 | 329 | 0.030 |
Why?
|
| Edible Grain | 1 | 2015 | 53 | 0.030 |
Why?
|
| Dairy Products | 1 | 2015 | 40 | 0.030 |
Why?
|
| Testosterone | 1 | 2001 | 638 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2010 | 4140 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2009 | 3107 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 440 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 5585 | 0.030 |
Why?
|
| Risk | 1 | 1998 | 1939 | 0.030 |
Why?
|
| Epidemiology | 1 | 2014 | 12 | 0.030 |
Why?
|
| Progestins | 1 | 2014 | 92 | 0.030 |
Why?
|
| CD-ROM | 1 | 2013 | 15 | 0.030 |
Why?
|
| Social Class | 2 | 2011 | 322 | 0.030 |
Why?
|
| Pamphlets | 1 | 2013 | 34 | 0.030 |
Why?
|
| Habits | 1 | 2013 | 37 | 0.030 |
Why?
|
| Resistance Training | 1 | 2013 | 39 | 0.030 |
Why?
|
| Electronic Mail | 1 | 2013 | 54 | 0.030 |
Why?
|
| Disease Progression | 1 | 2005 | 6828 | 0.030 |
Why?
|
| Faculty | 1 | 2014 | 132 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 792 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2022 | 8624 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1596 | 0.030 |
Why?
|
| Organizational Innovation | 1 | 2012 | 73 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2013 | 33701 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2000 | 1900 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 1255 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2012 | 75 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 4803 | 0.030 |
Why?
|
| Genotype | 2 | 2010 | 4251 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 1821 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2000 | 2117 | 0.020 |
Why?
|
| Databases, Factual | 1 | 1999 | 2233 | 0.020 |
Why?
|
| Health Surveys | 1 | 2013 | 400 | 0.020 |
Why?
|
| Health Promotion | 1 | 2015 | 510 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2011 | 52 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2017 | 725 | 0.020 |
Why?
|
| Prognosis | 3 | 2020 | 22473 | 0.020 |
Why?
|
| Parity | 1 | 2011 | 136 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2011 | 179 | 0.020 |
Why?
|
| Communication Barriers | 1 | 2011 | 52 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2016 | 2031 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2011 | 240 | 0.020 |
Why?
|
| Tetraspanin 24 | 1 | 2009 | 4 | 0.020 |
Why?
|
| Leisure Activities | 1 | 2009 | 17 | 0.020 |
Why?
|
| Hepatic Stellate Cells | 1 | 2009 | 30 | 0.020 |
Why?
|
| Comet Assay | 1 | 2009 | 57 | 0.020 |
Why?
|
| Anthropometry | 1 | 2009 | 264 | 0.020 |
Why?
|
| Social Environment | 1 | 2009 | 181 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 1997 | 4956 | 0.020 |
Why?
|
| Apoptosis | 2 | 2000 | 7753 | 0.020 |
Why?
|
| Social Support | 1 | 2011 | 593 | 0.020 |
Why?
|
| Schools | 1 | 2009 | 236 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2000 | 14622 | 0.020 |
Why?
|
| Cryptorchidism | 1 | 2007 | 49 | 0.020 |
Why?
|
| Child | 3 | 2015 | 30482 | 0.020 |
Why?
|
| Causality | 1 | 2007 | 177 | 0.020 |
Why?
|
| Pregnancy Trimester, First | 1 | 2007 | 126 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2009 | 882 | 0.020 |
Why?
|
| Pregnancy | 2 | 2011 | 8098 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2007 | 748 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 9041 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 6256 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2009 | 1418 | 0.010 |
Why?
|
| Prenatal Care | 1 | 2007 | 348 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2009 | 1272 | 0.010 |
Why?
|
| Cell Cycle | 2 | 2000 | 2137 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 3213 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 2000 | 5758 | 0.010 |
Why?
|
| Cathepsin D | 1 | 2001 | 33 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2007 | 832 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 4044 | 0.010 |
Why?
|
| DNA Repair | 1 | 2009 | 1910 | 0.010 |
Why?
|
| Genes, cdc | 1 | 2000 | 84 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2002 | 490 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 2000 | 164 | 0.010 |
Why?
|
| Cell Count | 1 | 2000 | 509 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2000 | 299 | 0.010 |
Why?
|
| Metribolone | 1 | 1999 | 49 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2000 | 537 | 0.010 |
Why?
|
| Plant Preparations | 1 | 1999 | 29 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2015 | 16997 | 0.010 |
Why?
|
| Genes, bcl-2 | 1 | 1999 | 172 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 1999 | 374 | 0.010 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1999 | 347 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1999 | 563 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2000 | 1126 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1999 | 806 | 0.010 |
Why?
|
| Registries | 1 | 2004 | 2203 | 0.010 |
Why?
|
| Cell Division | 1 | 2000 | 2661 | 0.010 |
Why?
|
| Androgens | 1 | 1999 | 509 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2001 | 1603 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 1999 | 1027 | 0.010 |
Why?
|
| Cell Survival | 1 | 2000 | 3061 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1999 | 1957 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 10384 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1999 | 1542 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 5071 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 1999 | 1580 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1999 | 2618 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1999 | 6394 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1999 | 4135 | 0.000 |
Why?
|
| Survival Rate | 1 | 2001 | 12513 | 0.000 |
Why?
|
| Time Factors | 1 | 2001 | 12989 | 0.000 |
Why?
|
| Neoplasm Proteins | 1 | 1999 | 3343 | 0.000 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2000 | 9040 | 0.000 |
Why?
|